Expanded Newborn Screening for Inborn Errors of Metabolism. Overview and Outcomes

Advances in Pediatrics

Volumn 59, Issue 1, 2012, Pages 209-245

  Sun, Angela ^a   Lam, Christina ^b   Wong, Derek A ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inborn errors of metabolism; Newborn screening; Outcomes; Tandem mass spectrometry

Indexed keywords

CLASSIFICATION; ETHICS; GENETICS; HUMAN; INBORN ERROR OF METABOLISM; METHODOLOGY; NEWBORN; NEWBORN SCREENING; REVIEW; TANDEM MASS SPECTROMETRY;

HUMANS; INFANT, NEWBORN; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 84863820659     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2012.04.013     Document Type: Review

References (266)

1. Fearing M.K., Levy H.L. Expanded newborn screening using tandem mass spectrometry. Adv Pediatr 2003, 50:81-111.
2. Watson M.S., Lloyd-Puryear M.A., Mann M.Y., et al. Main report. Genet Med 2006, 8(Suppl):12S-252S.
3. Fernhoff P.M. Newborn screening for genetic disorders. Pediatr Clin North Am 2009, 56(3):505-513. Table of Contents.
4. Lloyd-Puryear M.A., Brower A. Long-term follow-up in newborn screening: a systems approach for improving health outcomes. Genet Med 2010, 12(Suppl 12):S256-S260.
5. Fridovich-Keil J, Bean L, He M, et al. Epimerase deficiency galactosemia. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at: Accessed December 1, 2011. http://www.genetests.org.
6. Elsas L. Galactosemia. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at: Accessed December 1, 2011. http://www.genetests.org.
7. Langley S.D., Lai K., Dembure P.P., et al. Molecular basis for Duarte and Los Angeles variant galactosemia. Am J Hum Genet 1997, 60(2):366-372.
8. Fridovich-Keil JL, Walter JH. Galactosemia. In: Valle D, Beaudet AL, Vogelstein B, et al, editors. Scriver's Online Metabolic and Molecular Bases of Inherited Disease. 2006. Available ate: Accessed December 1, 2011. http://dx.doi.org/10.1036/ommbid.91.
9. Berry G.T., Segal S., Gitzelmann R. Disorders of galactose metabolism. Inborn metabolic diseases 2006, 121-130. Springer. 4th edition. J. Fernandes (Ed.).
10. Ficicioglu C., Yager C., Segal S. Galactitol and galactonate in red blood cells of children with the Duarte/galactosemia genotype. Mol Genet Metab 2005, 84(2):152-159.
11. Levy H.L., Sepe S.J., Walton D.S., et al. Galactose-1-phosphate uridyl transferase deficiency due to Duarte/galactosemia combined variation: clinical and biochemical studies. J Pediatr 1978, 92(3):390-393.
12. Schweitzer-Krantz S. Early diagnosis of inherited metabolic disorders towards improving outcome: the controversial issue of galactosaemia. Eur J Pediatr 2003, 162(Suppl 1):S50-S53.
13. Waggoner D.D., Buist N.R., Donnell G.N. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 1990, 13(6):802-818.
14. Fridovich-Keil J.L., Gubbels C.S., Spencer J.B., et al. Ovarian function in girls and women with GALT-deficiency galactosemia. J Inherit Metab Dis 2011, 34(2):357-366.
15. Schadewaldt P., Hoffmann B., Hammen H.W., et al. Longitudinal assessment of intellectual achievement in patients with classical galactosemia. Pediatrics 2010, 125(2):e374-e381.
16. Ficicioglu C., Thomas N., Yager C., et al. Duarte (DG) galactosemia: a pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening. Mol Genet Metab 2008, 95(4):206-212.
17. Powell K.K., Van Naarden Braun K., Singh R.H., et al. Long-term speech and language developmental issues among children with Duarte galactosemia. Genet Med 2009, 11(12):874-879.
18. Hennermann J.B., Schadewaldt P., Vetter B., et al. Features and outcome of galactokinase deficiency in children diagnosed by newborn screening. J Inherit Metab Dis 2011, 34(2):399-407.
19. Bosch A.M., Bakker H.D., van Gennip A.H., et al. Clinical features of galactokinase deficiency: a review of the literature. J Inherit Metab Dis 2002, 25(8):629-634.
20. Walter J.H., Roberts R.E., Besley G.T., et al. Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child 1999, 80(4):374-376.
21. Sarkar M., Bose S.S., Mondal G., et al. Generalized epimerase deficiency galactosemia. Indian J Pediatr 2010, 77(8):909-910.
22. Lindner M., Gramer G., Haege G., et al. Efficacy and outcome of expanded newborn screening for metabolic diseases-report of 10 years from South-West Germany. Orphanet J Rare Dis 2011, 6:44.
23. Mitchell J.J., Trakadis Y.J., Scriver C.R. Phenylalanine hydroxylase deficiency. Genet Med 2011, 13(8):697-707.
24. Enns G.M., Koch R., Brumm V., et al. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab 2010, 101(2-3):99-109.
25. Campistol J., Gassio R., Artuch R., et al. Neurocognitive function in mild hyperphenylalaninemia. Dev Med Child Neurol 2011, 53(5):405-408.
26. Hanley W.B. Non-PKU mild hyperphenylalaninemia (MHP)-the dilemma. Mol Genet Metab 2011, 104(1-2):23-26.
27. Scriver CR, Levy H, Donlon J. Hyperphenylalaninemia: Phenylalanine Hydroxylase Deficiency. In: Valle D, Beaudet AL, Vogelstein B, et al, editors. Scriver's Online Metabolic and Molecular Bases of Inherited Disease. 2006. Available at: Accessed December 1, 2011. http://dx.doi.org/10.1036/ommbid.97.
28. Abadie V., Berthelot J., Feillet F., et al. Neonatal screening and long-term follow-up of phenylketonuria: the French database. Early Hum Dev 2001, 65(2):149-158.
29. Chace D.H., Sherwin J.E., Hillman S.L., et al. Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. Clin Chem 1998, 44(12):2405-2409.
30. Ponzone A., Spada M., Ferraris S., et al. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 2004, 24(2):127-150.
31. Dhondt J.L. Lessons from 30 years of selective screening for tetrahydrobiopterin deficiency. J Inherit Metab Dis 2010, 33(Suppl 2):S219-S223.
32. Niu D.M. Disorders of BH4 metabolism and the treatment of patients with 6-pyruvoyl-tetrahydropterin synthase deficiency in Taiwan. Brain Dev 2011, 33(10):847-855.
33. Chien Y.H., Chiang S.C., Huang A., et al. Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations. J Inherit Metab Dis 2001, 24(8):815-823.
34. Vatanavicharn N., Kuptanon C., Liammongkolkul S., et al. Novel mutation affecting the pterin-binding site of PTS gene and review of PTS mutations in Thai patients with 6-pyruvoyltetrahydropterin synthase deficiency. J Inherit Metab Dis 2009.
35. Pangkanon S., Charoensiriwatanamsc W., Liamsuwanmd S. 6-Pyruvoyltetrahydropterin synthase deficiency two-case report. J Med Assoc Thai 2006, 89(6):872-877.
36. Jaggi L., Zurfluh M.R., Schuler A., et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 2008, 93(3):295-305.
37. Hutchesson A.C., Hall S.K., Preece M.A., et al. Screening for tyrosinaemia type I. Arch Dis Child Fetal Neonatal Ed 1996, 74(3):F191-F194.
38. Allard P., Grenier A., Korson M.S., et al. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004, 37(11):1010-1015.
39. Schlump J.U., Mayatepek E., Spiekerkoetter U. Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1. Eur J Pediatr 2010, 169(5):569-572.
40. Turgeon C., Magera M.J., Allard P., et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 2008, 54(4):657-664.
41. Morrissey M.A., Sunny S., Fahim A., et al. Newborn screening for Tyr-I: two years' experience of the New York State program. Mol Genet Metab 2011, 103(2):191-192.
42. Scott C.R. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet 2006, 142(2):121-126.
43. Barr D.G., Kirk J.M., Laing S.C. Outcome in tyrosinaemia type II. Arch Dis Child 1991, 66(10):1249-1250.
44. Meissner T., Betz R.C., Pasternack S.M., et al. Richner-Hanhart syndrome detected by expanded newborn screening. Pediatr Dermatol 2008, 25(3):378-380.
45. Fois A., Borgogni P., Cioni M., et al. Presentation of the data of the Italian Registry for Oculocutaneous Tyrosinemia. J Inherit Metab Dis 1986, 9:262-264.
46. Cerone R., Fantasia A.R., Castellano E., et al. Pregnancy and tyrosinaemia type II. J Inherit Metab Dis 2002, 25(4):317-318.
47. Ellaway C.J., Holme E., Standing S., et al. Outcome of tyrosinaemia type III. J Inherit Metab Dis 2001, 24(8):824-832.
48. Wilcken B., Hammond J.W., Howard N., et al. Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy. N Engl J Med 1981, 305(15):865-868.
49. Danks D.M., Tippett P., Rogers J. A new form of prolonged transient tyrosinemia presenting with severe metabolic acidosis. Acta Paediatr Scand 1975, 64(2):209-214.
50. Yap S., Naughten E. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis 1998, 21(7):738-747.
51. Yap S., Rushe H., Howard P.M., et al. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis 2001, 24(4):437-447.
52. Walter J.H., Wraith J.E., White F.J., et al. Strategies for the treatment of cystathionine beta-synthase deficiency: the experience of the Willink Biochemical Genetics Unit over the past 30 years. Eur J Pediatr 1998, 157(Suppl 2):S71-S76.
53. Mulvihill A., Yap S., O'Keefe M., et al. Ocular findings among patients with late-diagnosed or poorly controlled homocystinuria compared with a screened, well-controlled population. J AAPOS 2001, 5(5):311-315.
54. Peterschmitt M.J., Simmons J.R., Levy H.L. Reduction of false negative results in screening of newborns for homocystinuria. N Engl J Med 1999, 341(21):1572-1576.
55. Chamberlin M.E., Ubagai T., Mudd S.H., et al. Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. Am J Hum Genet 2000, 66(2):347-355.
56. Mudd S.H. Hypermethioninemias of genetic and non-genetic origin: a review. Am J Med Genet C Semin Med Genet 2011, 157(1):3-32.
57. Kim S.Z., Santamaria E., Jeong T.E., et al. Methionine adenosyltransferase I/III deficiency: two Korean compound heterozygous siblings with a novel mutation. J Inherit Metab Dis 2002, 25(8):661-671.
58. Couce M.L., Boveda M.D., Castineiras D.E., et al. Hypermethioninaemia due to methionine adenosyltransferase I/III (MAT I/III) deficiency: diagnosis in an expanded neonatal screening programme. J Inherit Metab Dis 2008, 31(Suppl 2):S233-S239.
59. Furujo M., Kinoshita M., Nagao M., et al. S-adenosylmethionine treatment in methionine adenosyltransferase deficiency, a case report. Mol Genet Metab 2012, 105(3):516-518.
60. Buist N.R., Glenn B., Vugrek O., et al. S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. J Inherit Metab Dis 2006, 29(4):538-545.
61. Grubbs R., Vugrek O., Deisch J., et al. S-adenosylhomocysteine hydrolase deficiency: two siblings with fetal hydrops and fatal outcomes. J Inherit Metab Dis 2010, 33(6):705-713.
62. McVoy J.R., Levy H.L., Lawler M., et al. Partial biotinidase deficiency: clinical and biochemical features. J Pediatr 1990, 116(1):78-83.
63. Wolf B., Spencer R., Gleason T. Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency. J Pediatr 2002, 140(2):242-246.
64. Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. J Inherit Metab Dis 1991, 14(6):923-927.
65. Moslinger D., Stockler-Ipsiroglu S., Scheibenreiter S., et al. Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria. Eur J Pediatr 2001, 160(5):277-282.
66. Weber P., Scholl S., Baumgartner E.R. Outcome in patients with profound biotinidase deficiency: relevance of newborn screening. Dev Med Child Neurol 2004, 46(7):481-484.
67. Hoffman T.L., Simon E.M., Ficicioglu C. Biotinidase deficiency: the importance of adequate follow-up for an inconclusive newborn screening result. Eur J Pediatr 2005, 164(5):298-301.
68. Simon E., Flaschker N., Schadewaldt P., et al. Variant maple syrup urine disease (MSUD)-the entire spectrum. J Inherit Metab Dis 2006, 29(6):716-724.
69. Simon E., Fingerhut R., Baumkotter J., et al. Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease. J Inherit Metab Dis 2006, 29(4):532-537.
70. Hoffmann B., Helbling C., Schadewaldt P., et al. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatr Res 2006, 59(1):17-20.
71. Morton D.H., Strauss K.A., Robinson D.L., et al. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 2002, 109(6):999-1008.
72. Riviello J.J., Rezvani I., DiGeorge A.M., et al. Cerebral edema causing death in children with maple syrup urine disease. J Pediatr 1991, 119(1 Pt 1):42-45.
73. Bhattacharya K., Khalili V., Wiley V., et al. Newborn screening may fail to identify intermediate forms of maple syrup urine disease. J Inherit Metab Dis 2006, 29(4):586.
74. Verdu A., Lopez-Herce J., Pascual-Castroviejo I., et al. Maple syrup urine disease variant form: presentation with psychomotor retardation and CT scan abnormalities. Acta Paediatr Scand 1985, 74(5):815-818.
75. Strauss KA, Puffenberger EG, Morton DH. Maple syrup urine disease. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at: Accessed December 1, 2011. http://www.genetests.org.
76. Chuang DT, Wynn RM, Shih VE. Maple Syrup Urine Disease (Branched-Chain Ketoaciduria), In: Valle D, Beaudet AL, Vogelstein B, et al, eds. Scriver's Online Metabolic and Molecular Bases of Inherited Disease. 2006. Available at: Accessed December 1, 2011. http://dx.doi.org/10.1036/ommbid.113.
77. Valman H.B., Patrick A.D., Seakins J.W., et al. Family with intermittent maple syrup urine disease. Arch Dis Child 1973, 48(3):225-228.
78. Puckett R.L., Lorey F., Rinaldo P., et al. Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms. Mol Genet Metab 2010, 100(2):136-142.
79. Baykal T., Karaaslan I., Gokcay G., et al. Hyperhydroxyprolinaemia detected in newborn screening with tandem mass spectrometry. J Inherit Metab Dis 2004, 27(6):781-782.
80. Matern D., Tortorelli S., Oglesbee D., et al. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis 2007, 30(4):585-592.
81. Bachmann C. Long-term outcome of patients with urea cycle disorders and the question of neonatal screening. Eur J Pediatr 2003, 162(Suppl 1):S29-S33.
82. Wilcken B. The consequences of extended newborn screening programmes: do we know who needs treatment?. J Inherit Metab Dis 2008, 31:173-177.
83. Batshaw M.L., Berry G.T. Use of citrulline as a diagnostic marker in the prospective treatment of urea cycle disorders. J Pediatr 1991, 118(6):914-917.
84. Cavicchi C., Malvagia S., la Marca G., et al. Hypocitrullinemia in expanded newborn screening by LC-MS/MS is not a reliable marker for ornithine transcarbamylase deficiency. J Pharm Biomed Anal 2009, 49(5):1292-1295.
85. Sander J., Janzen N., Sander S., et al. Neonatal screening for citrullinaemia. Eur J Pediatr 2003, 162(6):417-420.
86. Haberle J., Pauli S., Schmidt E., et al. Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1). Mol Genet Metab 2003, 80(3):302-306.
87. Glamuzina E., Marquis-Nicholson R., Knoll D., et al. Citrullinaemia type I: a common mutation in the Pacific Island population. J Paediatr Child Health 2011, 47(5):262-265.
88. Ficicioglu C., Mandell R., Shih V.E. Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening. Mol Genet Metab 2009, 98(3):273-277.
89. Mercimek-Mahmutoglu S., Moeslinger D., Haberle J., et al. Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab 2010, 100(1):24-28.
90. Crombez E.A., Cederbaum S.D. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab 2005, 84(3):243-251.
91. Sokoro A.A., Lepage J., Antonishyn N., et al. Diagnosis and high incidence of hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome in northern Saskatchewan. J Inherit Metab Dis 2010.
92. Ibarra-Gonzalez I., Fernandez-Lainez C., Vela-Amieva M. Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country. Clin Biochem 2010, 43(4-5):461-466.
93. Tamamori A., Fujimoto A., Okano Y., et al. Effects of citrin deficiency in the perinatal period: feasibility of newborn mass screening for citrin deficiency. Pediatr Res 2004, 56(4):608-614.
94. Seashore M.R. The Organic Acidemias: an overview. GeneReviews at GeneTests Medical Genetics Information Resource (database online) 1997-2012, University of Washington, Seattle, Available at: http://www.genetests.org. Accessed December 1, 2011.
95. Newborn Screening Coding and Terminology Guide. [Text] 2011 November 7, 2011 [cited 2012 January 10, 2012]. Available at: Accessed December 1, 2011. http://newbornscreeningcodes.nlm.nih.gov/.
96. Yorifuji T., Kawai M., Muroi J., et al. Unexpectedly high prevalence of the mild form of propionic acidemia in Japan: presence of a common mutation and possible clinical implications. Hum Genet 2002, 111(2):161-165.
97. Dionisi-Vici C., Deodato F., Roschinger W., et al. 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis 2006, 29(2-3):383-389.
98. la Marca G., Malvagia S., Pasquini E., et al. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false-positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography-tandem mass spectrometry. Clin Chem 2007, 53(7):1364-1369.
99. Ensenauer R., Fingerhut R., Maier E.M., et al. Newborn screening for isovaleric acidemia using tandem mass spectrometry: data from 1.6 million newborns. Clin Chem 2011, 57(4):623-626.
100. Vockley J., Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet 2006, 142(2):95-103.
101. Ensenauer R., Vockley J., Willard J.M., et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 2004, 75(6):1136-1142.
102. Lee Y.W., Lee D.H., Vockley J., et al. Different spectrum of mutations of isovaleryl-CoA dehydrogenase (IVD) gene in Korean patients with isovaleric acidemia. Mol Genet Metab 2007, 92(1-2):71-77.
103. Lin W.D., Wang C.H., Lee C.C., et al. Genetic mutation profile of isovaleric acidemia patients in Taiwan. Mol Genet Metab 2007, 90(2):134-139.
104. Leonard J.V., Vijayaraghavan S., Walter J.H. The impact of screening for propionic and methylmalonic acidaemia. Eur J Pediatr 2003, 162(Suppl 1):S21-S24.
105. Hsieh S.H., Cheng P.H., Chen C.H., et al. A multi-voting enhancement for newborn screening healthcare information system. J Med Syst 2010, 34(4):727-733.
106. Lee N.C., Chien Y.H., Peng S.F., et al. Brain damage by mild metabolic derangements in methylmalonic acidemia. Pediatr Neurol 2008, 39(5):325-329.
107. Nyhan W.L., Gargus J.J., Boyle K., et al. Progressive neurologic disability in methylmalonic acidemia despite transplantation of the liver. Eur J Pediatr 2002, 161(7):377-379.
108. Weisfeld-Adams J.D., Morrissey M.A., Kirmse B.M., et al. Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. Mol Genet Metab 2010, 99(2):116-123.
109. Lin H.J., Neidich J.A., Salazar D., et al. Asymptomatic maternal combined homocystinuria and methylmalonic aciduria (cblC) detected through low carnitine levels on newborn screening. J Pediatr 2009, 155(6):924-927.
110. Arnold G.L., Koeberl D.D., Matern D., et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 2008, 93(4):363-370.
111. Koeberl D.D., Millington D.S., Smith W.E., et al. Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis 2003, 26(1):25-35.
112. Frazier D.M., Millington D.S., McCandless S.E., et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005. J Inherit Metab Dis 2006, 29(1):76-85.
113. Ficicioglu C., Payan I. 3-Methylcrotonyl-CoA carboxylase deficiency: metabolic decompensation in a noncompliant child detected through newborn screening. Pediatrics 2006, 118(6):2555-2556.
114. Stadler S.C., Polanetz R., Maier E.M., et al. Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment. Hum Mutat 2006, 27(8):748-759.
115. Lund A.M., Joensen F., Hougaard D.M., et al. Carnitine transporter and holocarboxylase synthetase deficiencies in The Faroe Islands. J Inherit Metab Dis 2007, 30(3):341-349.
116. Baumgartner E.R., Suormala T. Multiple carboxylase deficiency: inherited and acquired disorders of biotin metabolism. Int J Vitam Nutr Res 1997, 67(5):377-384.
117. Nyhan W.L., Willis M., Barshop B.A., et al. Positive newborn screen in the biochemically normal infant of a mother with treated holocarboxylase synthetase deficiency. J Inherit Metab Dis 2010.
118. Korman S.H. Inborn errors of isoleucine degradation: a review. Mol Genet Metab 2006, 89(4):289-299.
119. Klose D.A., Kolker S., Heinrich B., et al. Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics 2002, 110(6):1204-1211.
120. Gibson K.M., Burlingame T.G., Hogema B., et al. 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of L-isoleucine metabolism. Pediatr Res 2000, 47(6):830-833.
121. Andresen B.S., Christensen E., Corydon T.J., et al. Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase deficiency: identification of a new enzyme defect, resolution of its molecular basis, and evidence for distinct acyl-CoA dehydrogenases in isoleucine and valine metabolism. Am J Hum Genet 2000, 67(5):1095-1103.
122. Kanavin O.J., Woldseth B., Jellum E., et al. 2-Methylbutyryl-CoA dehydrogenase deficiency associated with autism and mental retardation: a case report. J Med Case Rep 2007, 1:98.
123. Matern D., He M., Berry S.A., et al. Prospective diagnosis of 2-methylbutyryl-CoA dehydrogenase deficiency in the Hmong population by newborn screening using tandem mass spectrometry. Pediatrics 2003, 112(1 Pt 1):74-78.
124. Alfardan J., Mohsen A.W., Copeland S., et al. Characterization of new ACADSB gene sequence mutations and clinical implications in patients with 2-methylbutyrylglycinuria identified by newborn screening. Mol Genet Metab 2010, 100(4):333-338.
125. Knerr I., Weinhold N., Vockley J., et al. Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects. J Inherit Metab Dis 2012, 35(1):29-40.
126. Madsen P.P., Kibaek M., Roca X., et al. Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3+3A>G mutation that causes exon skipping. Hum Genet 2006, 118(6):680-690.
127. van Calcar S.C., Gleason L.A., Lindh H., et al. 2-Methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. WMJ 2007, 106(1):12-15.
128. Sass J.O., Ensenauer R., Roschinger W., et al. 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: functional and molecular studies on a defect in isoleucine catabolism. Mol Genet Metab 2008, 93(1):30-35.
129. Sarafoglou K., Matern D., Redlinger-Grosse K., et al. Siblings with mitochondrial acetoacetyl-CoA thiolase deficiency not identified by newborn screening. Pediatrics 2011, 128(1):e246-e250.
130. Wiley V., Carpenter K., Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. Acta Paediatr Suppl 1999, 88(432):48-51.
131. Catanzano F., Ombrone D., Di Stefano C., et al. The first case of mitochondrial acetoacetyl-CoA thiolase deficiency identified by expanded newborn metabolic screening in Italy: the importance of an integrated diagnostic approach. J Inherit Metab Dis 2010.
132. Kolker S., Christensen E., Leonard J.V., et al. Diagnosis and management of glutaric aciduria type I-revised recommendations. J Inherit Metab Dis 2011, 34(3):677-694.
133. Gallagher R.C., Cowan T.M., Goodman S.I., et al. Glutaryl-CoA dehydrogenase deficiency and newborn screening: retrospective analysis of a low excretor provides further evidence that some cases may be missed. Mol Genet Metab 2005, 86(3):417-420.
134. Smith W.E., Millington D.S., Koeberl D.D., et al. Glutaric acidemia, type I, missed by newborn screening in an infant with dystonia following promethazine administration. Pediatrics 2001, 107(5):1184-1187.
135. Niu D.M., Chien Y.H., Chiang C.C., et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis 2010, 33(Suppl 2):S295-S305.
136. Greenberg C.R., Prasad A.N., Dilling L.A., et al. Outcome of the first 3-years of a DNA-based neonatal screening program for glutaric acidemia type 1 in Manitoba and northwestern Ontario, Canada. Mol Genet Metab 2002, 75(1):70-78.
137. Bijarnia S., Wiley V., Carpenter K., et al. Glutaric aciduria type I: outcome following detection by newborn screening. J Inherit Metab Dis 2008, 31(4):503-507.
138. Yang L., Yin H., Yang R., et al. Diagnosis, treatment and outcome of glutaric aciduria type I in Zhejiang Province, China. Med Sci Monit 2011, 17(7):PH55-PH59.
139. Boneh A., Beauchamp M., Humphrey M., et al. Newborn screening for glutaric aciduria type I in Victoria: treatment and outcome. Mol Genet Metab 2008, 94(3):287-291.
140. Beauchamp M.H., Boneh A., Anderson V. Cognitive, behavioural and adaptive profiles of children with glutaric aciduria type I detected through newborn screening. J Inherit Metab Dis 2009.
141. Kolker S., Garbade S.F., Boy N., et al. Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany. Pediatr Res 2007, 62(3):357-363.
142. Kolker S., Garbade S.F., Greenberg C.R., et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 2006, 59(6):840-847.
143. Holiner I., Simma B., Reiter A., et al. Compliance to clinical guidelines determines outcome in glutaric aciduria type I in the era of newborn screening. Klin Padiatr 2010, 222(1):35-37.
144. Vilarinho L., Rocha H., Sousa C., et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 2010.
145. Crombez E.A., Cederbaum S.D., Spector E., et al. Maternal glutaric acidemia, type I identified by newborn screening. Mol Genet Metab 2008, 94(1):132-134.
146. Garcia P., Martins E., Diogo L., et al. Outcome of three cases of untreated maternal glutaric aciduria type I. Eur J Pediatr 2008, 167(5):569-573.
147. Roe C.R., Cederbaum S.D., Roe D.S., et al. Isolated isobutyryl-CoA dehydrogenase deficiency: an unrecognized defect in human valine metabolism. Mol Genet Metab 1998, 65(4):264-271.
148. Sass J.O., Sander S., Zschocke J. Isobutyryl-CoA dehydrogenase deficiency: isobutyrylglycinuria and ACAD8 gene mutations in two infants. J Inherit Metab Dis 2004, 27(6):741-745.
149. Oglesbee D., He M., Majumder N., et al. Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. Genet Med 2007, 9(2):108-116.
150. Koeberl D.D., Young S.P., Gregersen N.S., et al. Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. Pediatr Res 2003, 54(2):219-223.
151. Yoo E.H., Cho H.J., Ki C.S., et al. Isobutyryl-CoA dehydrogenase deficiency with a novel ACAD8 gene mutation detected by tandem mass spectrometry newborn screening. Clin Chem Lab Med 2007, 45(11):1495-1497.
152. Pedersen C.B., Bischoff C., Christensen E., et al. Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening. Pediatr Res 2006, 60(3):315-320.
153. Popek M., Walter M., Fernando M., et al. Two inborn errors of metabolism in a newborn: glutaric aciduria type I combined with isobutyrylglycinuria. Clin Chim Acta 2010, 411(23-24):2087-2091.
154. Zschocke J., Hoffmann G.F. Vademecum metabolicum manual of metabolic paediatrics 2004, F.K. Schattauer, Friedricksdorf (Germany). 2nd edition.
155. Ly T.B., Peters V., Gibson K.M., et al. Mutations in the AUH gene cause 3-methylglutaconic aciduria type I. Hum Mutat 2003, 21(4):401-407.
156. Yoon H.R., Hahn S.H., Ahn Y.M., et al. Therapeutic trial in the first three Asian cases of ethylmalonic encephalopathy: response to riboflavin. J Inherit Metab Dis 2001, 24(8):870-873.
157. Viscomi C., Burlina A.B., Dweikat I., et al. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 2010, 16(8):869-871.
158. Di Rocco M., Caruso U., Briem E., et al. A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation. Mol Genet Metab 2006, 89(4):395-397.
159. Grosso S., Mostardini R., Farnetani M.A., et al. Ethylmalonic encephalopathy: further clinical and neuroradiological characterization. J Neurol 2002, 249(10):1446-1450.
160. Pigeon N., Campeau P.M., Cyr D., et al. Clinical heterogeneity in ethylmalonic encephalopathy. J Child Neurol 2009, 24(8):991-996.
161. de Wit M.C., de Coo I.F., Verbeek E., et al. Brain abnormalities in a case of malonyl-CoA decarboxylase deficiency. Mol Genet Metab 2006, 87(2):102-106.
162. Salomons G.S., Jakobs C., Pope L.L., et al. Clinical, enzymatic and molecular characterization of nine new patients with malonyl-coenzyme A decarboxylase deficiency. J Inherit Metab Dis 2007, 30(1):23-28.
163. Moczulski D., Majak I., Mamczur D. An overview of beta-oxidation disorders. Postepy Hig Med Dosw (Online) 2009, 63:266-277.
164. Matern D., Hart P., Murtha A.P., et al. Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 2001, 138(4):585-588.
165. Nelson J., Lewis B., Walters B. The HELLP syndrome associated wiht fetal medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2000, 23(5):518-519.
166. Santos L., Patterson A., Moreea S.M., et al. Acute liver failure in pregnancy associated with maternal MCAD deficiency. J Inherit Metab Dis 2007, 30(1):103.
167. Innes A.M., Seargeant L.E., Balachandra K., et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000, 47(1):43-45.
168. Wilcken B., Leung K.C., Hammond J., et al. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993, 341(8842):407-408.
169. Chakrapani A., Olpin S., Cleary M., et al. Trifunctional protein deficiency: three families with significant maternal hepatic dysfunction in pregnancy not associated with E474Q mutation. J Inherit Metab Dis 2000, 23(8):826-834.
170. Schimmenti L.A., Crombez E.A., Schwahn B.C., et al. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol Genet Metab 2007, 90(4):441-445.
171. El-Hattab A.W., Li F.Y., Shen J., et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med 2010, 12(1):19-24.
172. Gibson K.M., Bennett M.J., Naylor E.W., et al. 3-Methylcrotonyl-coenzyme A carboxylase deficiency in Amish/Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. J Pediatr 1998, 132(3 Pt 1):519-523.
173. Leydiker K.B., Neidich J.A., Lorey F., et al. Maternal medium-chain acyl-CoA dehydrogenase deficiency identified by newborn screening. Mol Genet Metab 2011, 103(1):92-95.
174. McGoey R.R., Marble M. Positive newborn screen in a normal infant of a mother with asymptomatic very long-chain Acyl-CoA dehydrogenase deficiency. J Pediatr 2011, 158(6):1031-1032.
175. Waisbren S.E., Levy H.L., Noble M., et al. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms. Mol Genet Metab 2008, 95(1-2):39-45.
176. Nagan N., Kruckeberg K.E., Tauscher A.L., et al. The frequency of short-chain acyl-CoA dehydrogenase gene variants in the US population and correlation with the C(4)-acylcarnitine concentration in newborn blood spots. Mol Genet Metab 2003, 78(4):239-246.
177. van Maldegem B.T., Duran M., Wanders R.J., et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 2006, 296(8):943-952.
178. van Maldegem B.T., Wanders R.J., Wijburg F.A. Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2010, 33(5):507-511.
179. Jethva R., Bennett M.J., Vockley J. Short-chain acyl-coenzyme A dehydrogenase deficiency. Mol Genet Metab 2008, 95(4):195-200.
180. Touma E.H., Charpentier C. Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child 1992, 67(1):142-145.
181. Iafolla A.K., Thompson R.J., Roe C.R. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994, 124(3):409-415.
182. Wilcken B., Haas M., Joy P., et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 2007, 369(9555):37-42.
183. Wilcken B., Haas M., Joy P., et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009, 124(2):e241-e248.
184. Roe C.R., Millington D.S., Maltby D.A., et al. Recognition of medium-chain acyl-CoA dehydrogenase deficiency in asymptomatic siblings of children dying of sudden infant death or Reye-like syndromes. J Pediatr 1986, 108(1):13-18.
185. Bennett M.J., Rinaldo P., Millington D.S., et al. Medium-chain acyl-CoA dehydrogenase deficiency: postmortem diagnosis in a case of sudden infant death and neonatal diagnosis of an affected sibling. Pediatr Pathol 1991, 11(6):889-895.
186. Yusupov R., Finegold D.N., Naylor E.W., et al. Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening. Mol Genet Metab 2010, 101(1):33-39.
187. Maier E.M., Liebl B., Roschinger W., et al. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 2005, 25(5):443-452.
188. Matern D, Rinaldo P. Medium-Chain Acyl-Coenzyme a dehydrogenase deficiency. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at: Accessed December 1, 2011. http://www.genetests.org.
189. Leslie N.D., Tinkle B.T., Strauss A. Overweight and obesity. GeneReviews 1993, McGraw Hill, New York, Available at:, Accessed December 1, 2011. http://www.genetests.org, R.A. Pagon (Ed.).
190. Browning M.F., Larson C., Strauss A., et al. Normal acylcarnitine levels during confirmation of abnormal newborn screening in long-chain fatty acid oxidation defects. J Inherit Metab Dis 2005, 28(4):545-550.
191. Sahai I., Bailey J.C., Eaton R.B., et al. A near-miss: very long chain acyl-CoA dehydrogenase deficiency with normal primary markers in the initial well-timed newborn screening specimen. J Pediatr 2011, 158(1):172. [author reply: 172-3].
192. Boneh A., Andresen B.S., Gregersen N., et al. VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 2006, 88(2):166-170.
193. Schymik I., Liebig M., Mueller M., et al. Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. J Pediatr 2006, 149(1):128-130.
194. Ficicioglu C., Coughlin C.R., Bennett M.J., et al. Very long-chain acyl-CoA dehydrogenase deficiency in a patient with normal newborn screening by tandem mass spectrometry. J Pediatr 2010, 156(3):492-494.
195. ACMG ACT Sheets and Confirmatory Algorithms [Internet] 2001, American College of Medical Genetics, Bethesda (MD), Available at:, Accessed December 1, 2011. http://www.ncbi.nlm.nih.gov/books/NBK55832/.
196. Andresen B.S., Olpin S., Poorthuis B.J., et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 1999, 64(2):479-494.
197. Spiekerkoetter U., Sun B., Zytkovicz T., et al. MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 2003, 143(3):335-342.
198. Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 2010, 33(5):501-506.
199. Spiekerkoetter U., Lindner M., Santer R., et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 2009, 32(4):488-497.
200. Bonnefont J.P., Djouadi F., Prip-Buus C., et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 2004, 25(5-6):495-520.
201. Longo N., Amat di San Filippo C., Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006, 142(2):77-85.
202. Gessner B.D., Gillingham M.B., Johnson M.A., et al. Prevalence and distribution of the c.1436C→T sequence variant of carnitine palmitoyltransferase 1A among Alaska Native infants. J Pediatr 2011, 158(1):124-129.
203. Gessner B.D., Gillingham M.B., Birch S., et al. Evidence for an association between infant mortality and a carnitine palmitoyltransferase 1A genetic variant. Pediatrics 2010, 126(5):945-951.
204. Gillingham M.B., Hirschfeld M., Lowe S., et al. Impaired fasting tolerance among Alaska native children with a common carnitine palmitoyltransferase 1A sequence variant. Mol Genet Metab 2011, 104(3):261-264.
205. Illsinger S., Lucke T., Peter M., et al. Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. Am J Med Genet A 2008, 146(22):2925-2928.
206. Wilcken B. Disorders of the carnitine cycle and detection by newborn screening. Ann Acad Med Singapore 2008, 37(Suppl 12):71-73.
207. Martinez G, Ribes A, Garavaglia B, et al. Favourable clinical evolution in a 20-year old girl with the infantile form of carnitine palmitoyltransferase II deficiency, in 7th International Congress of Inborn Errors of Metabolism. Vienna (Austria), May 21-25, 1997.
208. Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 2010, 33(5):527-532.
209. Pierre G., Macdonald A., Gray G., et al. Prospective treatment in carnitine-acylcarnitine translocase deficiency. J Inherit Metab Dis 2007, 30(5):815.
210. Al-Sannaa N.A., Cheriyan G.M. Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype. Saudi Med J 2010, 30(8):931-934.
211. Iacobazzi V., Pasquali M., Singh R., et al. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A 2004, 126(2):150-155.
212. Olpin S.E., Bonham J.R., Downing M., et al. Carnitine-acylcarnitine translocase deficiency-a mild phenotype. J Inherit Metab Dis 1997, 20(5):714-715.
213. Lopriore E., Gemke R.J., Verhoeven N.M., et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 2001, 160(2):101-104.
214. Bargen-Lockner C., Hahn P., Wittmann B. Plasma carnitine in pregnancy. Am J Obstet Gynecol 1981, 140(4):412-414.
215. Schoderbeck M., Auer B., Legenstein E., et al. Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes. J Perinat Med 1995, 23(6):477-485.
216. Lee N.C., Tang N.L., Chien Y.H., et al. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol Genet Metab 2010, 100(1):46-50.
217. Stanley C.A. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004, 1033:42-51.
218. Rinaldo P., Stanley C.A., Hsu B.Y., et al. Sudden neonatal death in carnitine transporter deficiency. J Pediatr 1997, 131(2):304-305.
219. Melegh B., Bene J., Mogyorosy G., et al. Phenotypic manifestations of the OCTN2 V295X mutation: sudden infant death and carnitine-responsive cardiomyopathy in Roma families. Am J Med Genet A 2004, 131(2):121-126.
220. Vijay S., Patterson A., Olpin S., et al. Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants. J Inherit Metab Dis 2006, 29(5):627-630.
221. Cederbaum S.D., Koo-McCoy S., Tein I., et al. Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol Genet Metab 2002, 77(3):195-201.
222. Cano A., Ovaert C., Vianey-Saban C., et al. Carnitine membrane transporter deficiency: a rare treatable cause of cardiomyopathy and anemia. Pediatr Cardiol 2008, 29(1):163-165.
223. Sperk A., Mueller M., Spiekerkoetter U. Outcome in six patients with mitochondrial trifunctional protein disorders identified by newborn screening. Mol Genet Metab 2010, 101(2-3):205-207.
224. Sander J., Sander S., Steuerwald U., et al. Neonatal screening for defects of the mitochondrial trifunctional protein. Mol Genet Metab 2005, 85(2):108-114.
225. Martins E., Cardoso M.L., Rodrigues E., et al. Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: the clinical relevance of an early diagnosis and report of four new cases. J Inherit Metab Dis 2011, 34(3):835-842.
226. Molven A., Matre G.E., Duran M., et al. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes 2004, 53(1):221-227.
227. Treacy E.P., Lambert D.M., Barnes R., et al. Short-chain hydroxyacyl-coenzyme A dehydrogenase deficiency presenting as unexpected infant death: a family study. J Pediatr 2000, 137(2):257-259.
228. Bennett M.J., Spotswood S.D., Ross K.F., et al. Fatal hepatic short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: clinical, biochemical, and pathological studies on three subjects with this recently identified disorder of mitochondrial beta-oxidation. Pediatr Dev Pathol 1999, 2(4):337-345.
229. Pollard L.M., Williams N.R., Espinoza L., et al. Diagnosis, treatment, and long-term outcomes of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency. J Child Neurol 2010, 25(8):954-960.
230. Vockley J. Glutaric aciduria type 2 and newborn screening: commentary. Mol Genet Metab 2008, 93(1):5-6.
231. Harpey J.P., Charpentier C., Coude M., et al. Sudden infant death syndrome and multiple acyl-coenzyme A dehydrogenase deficiency, ethylmalonic-adipic aciduria, or systemic carnitine deficiency. J Pediatr 1987, 110(6):881-884.
232. Lundemose J.B., Kolvraa S., Gregersen N., et al. Fatty acid oxidation disorders as primary cause of sudden and unexpected death in infants and young children: an investigation performed on cultured fibroblasts from 79 children who died aged between 0-4 years. Mol Pathol 1997, 50(4):212-217.
233. Angle B., Burton B.K. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008, 93(1):36-39.
234. Singla M., Guzman G., Griffin A.J., et al. Cardiomyopathy in multiple Acyl-CoA dehydrogenase deficiency: a clinico-pathological correlation and review of literature. Pediatr Cardiol 2008, 29(2):446-451.
235. Wang R.Y., Bodamer O.A., Watson M.S., et al. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 2011, 13(5):457-484.
236. Newborn screening: toward a uniform screening panel and system. Genet Med 2006, 8(Suppl 1):1S-252S.
237. Reuser A.J., Verheijen F.W., Bali D., et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders - Current status and perspectives. Mol Genet Metab 2011, 104(1-2):144-148.
238. Kemper A.R., Hwu W-L., Lloyd-Puryear M., et al. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics 2007, 120(5):E1327-E1334.
239. Kumamoto S., Katafuchi T., Nakamura K., et al. High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. Mol Genet Metab 2009, 97(3):190-195.
240. Shigeto S., Katafuchi T., Okada Y., et al. Improved assay for differential diagnosis between Pompe disease and acid alpha-glucosidase pseudodeficiency on dried blood spots. Mol Genet Metab 2011, 103(1):12-17.
241. Chien Y.H., Lee N-C., Thurberg B.L., et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009, 124(6):E1116-E1125.
242. Escolar M.L., Poe M.D., Provenzale J.M., et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005, 352(20):2069-2081.
243. Duffner P.K., Caviness V.S., Erbe R.W., et al. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 2009, 11(6):450-454.
244. Lim Z.Y., Ho A.Y., Abrahams S., et al. Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplant 2008, 41(9):831-832.
245. Duffner P.K., Caggana M., Orsini J.J., et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009, 40(4):245-252. [discussion: 253-5].
246. Wang R.Y., Lelis A., Mirocha J., et al. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007, 9(1):34-45.
247. Hwu W.L., Chien Y.H., Lee N.C., et al. Newborn screening for fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G > A (IVS4+919G > A). Hum Mutat 2009, 30(10):1397-1405.
248. Spada M., Pagliardini S., Yasuda M., et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006, 79(1):31-40.
249. Lin H.Y., Chong K.W., Hsu J.H., et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009, 2(5):450-456.
250. Wilson J.M., Jungner Y.G. Bol Oficina Sanit Panam 1968, 65(4):281-393. [in Spanish].
251. Hewlett J., Waisbren S.E. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis 2006, 29(5):677-682.
252. Gurian E.A., Kinnamon D.D., Henry J.J., et al. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006, 117(6):1915-1921.
253. Sorenson J.R., Levy H.L., Mangione T.W., et al. Parental response to repeat testing of infants with 'false-positive' results in a newborn screening program. Pediatrics 1984, 73(2):183-187.
254. Timmermans S., Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav 2010, 51(4):408-423.
255. DeLuca J.M., Kearney M.H., Norton S.A., et al. Parents' experiences of expanded newborn screening evaluations. Pediatrics 2011, 128(1):53-61.
256. Wenger D.A., Rafi M.A., Luzi P., et al. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab 2000, 70(1):1-9.
257. Wenger DA, Suzuki K, Suzuki Y, et al. Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe Disease). In: Valle D, Beaudet AL, Vogelstein B, et al, editors. Scriver's Online Metabolic and Molecular Bases of Inherited Disease. 2006. Available at: .178. Accessed December 1, 2011. http://dx.doi.org/10.1036/ommbid.
258. Hudson K.L., Holohan M.K., Collins F.S. Keeping pace with the times-the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 2008, 358(25):2661-2663.
259. Erwin C. Legal update: living with the genetic information nondiscrimination act. Genet Med 2008, 10(12):869-873.
260. Sewell A.C., Gebhardt B., Herwig J., et al. Acceptance of extended newborn screening: the problem of parental non-compliance. Eur J Pediatr 2004, 163(12):755-756.
261. Dhondt J.L. Expanded newborn screening: social and ethical issues. J Inherit Metab Dis 2010, 33(Suppl 2):S211-S217.
262. Wilcken B. Ethical issues in newborn screening and the impact of new technologies. Eur J Pediatr 2003, 162(Suppl 1):S62-S66.
263. Kerruish N.J., Robertson S.P. Newborn screening: new developments, new dilemmas. J Med Ethics 2005, 31(7):393-398.
264. Tortorelli S., Turgeon C.T., Lim J.S., et al. Two-tier approach to the newborn screening of methylenetetrahydrofolate reductase deficiency and other remethylation disorders with tandem mass spectrometry. J Pediatr 2010, 157(2):271-275.
265. Carducci C., Santagata S., Leuzzi V., et al. Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry. Clin Chim Acta 2006, 364(1-2):180-187.
266. McHugh D.M., Cameron C.A., Abdenur J.E., et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011, 13(3):230-254.